tiprankstipranks
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
Australian Market
NEU
Neuren Pharmaceuticals Limited
RESEARCH TOOLSreports
Want to see AU:NEU full AI Analyst Report?

Neuren Pharmaceuticals Limited (NEU) Earnings Dates, Call Summary & Reports

282 Followers

Earnings Data

Report Date
Aug 25, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.04
Last Year’s EPS
0.12
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2023
Earnings Call Date:Feb 29, 2024|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted Neuren's strong financial performance, significant cash growth, and successful collaboration with Acadia. Positive trial results for NNZ-2591 and an expanded global reach were significant achievements. However, challenges such as tax liabilities, exchange rate impacts, and share price volatility were noted. Overall, the positive aspects and strategic advancements overshadow the lowlights.
Company Guidance
During Neuren's 2023 earnings call, CEO Jonathan Pilcher highlighted several key financial metrics. The company reported a profit of AUD 157 million, fueled by AUD 27 million in royalty income, a USD 59 million milestone payment from DAYBUE's first commercial sale in the U.S., and USD 146 million from an expanded deal with Acadia. Cash reserves increased from AUD 40 million to AUD 229 million without any capital raising. Neuren anticipates royalty income between AUD 61 million and AUD 70 million next year, based on a royalty rate that ranges from 10% to 12%. Additionally, Neuren is expecting USD 50 million in milestone payments as DAYBUE's sales exceed USD 250 million. Neuren's R&D expenses totaled AUD 27 million, with significant efforts directed towards four Phase II trials and preparations for Phase III. Acadia's DAYBUE guidance for 2024 forecasts USD 370 million to USD 420 million in sales, indicating substantial growth from 2023's USD 177 million.
Record Profit and Cash Growth
Neuren reported a profit of AUD 157 million, with cash growing from $40 million to $229 million without any capital raising.
Strong Financial Performance from Acadia Partnership
Neuren received $27 million of royalty income, $59 million from DAYBUE's first commercial sale milestone, and $146 million from an expanded deal with Acadia.
Successful DAYBUE Sales
DAYBUE net sales in Q4 reached USD 87 million, hitting the top of Acadia's guidance. Total sales for the partial year were USD 177 million, with 2024 guidance between USD 370 million and USD 420 million.
Expanded Global Reach
The deal with Acadia expanded to include markets outside North America, bringing in USD 100 million upfront, with tiered royalties from mid-teens to low 20s expected once they reach the market.
Positive Phase II Trial Results for NNZ-2591
Outstanding results announced for the Phelan-McDermid syndrome trial, exceeding expectations and showing consistent improvements across multiple efficacy measures.

Neuren Pharmaceuticals Limited (AU:NEU) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

AU:NEU Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 25, 2026
2026 (Q2)
0.04 / -
0.119―――
Feb 26, 2026
2025 (Q4)
0.01 / 0.12
1.022-88.45% (-0.90)――
Aug 26, 2025
2025 (Q2)
0.12 / 0.12
0.06195.08% (+0.06)――
Feb 27, 2025
2024 (Q4)
1.04 / 1.02
0.8618.84% (+0.16)
Aug 27, 2024
2024 (Q2)
0.11 / 0.06
0.368-83.42% (-0.31)――
Feb 29, 2024
2023 (Q4)
0.98 / 0.86
0.0571408.77% (+0.80)
Aug 27, 2023
2023 (Q2)
0.32 / 0.37
-0.056757.14% (+0.42)―
Feb 23, 2023
2022 (Q4)
- / 0.06
0.0015600.00% (+0.06)――
Aug 23, 2022
2022 (Q2)
- / -0.06
-0.0720.00% (+0.01)――
Feb 23, 2022
2021 (Q4)
- / <0.01
-0.038102.63% (+0.04)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

AU:NEU Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 26, 2026
AU$13.44AU$13.05-2.90%
Aug 26, 2025
AU$17.80AU$19.00+6.74%
Feb 27, 2025
AU$14.20AU$13.23-6.83%
Aug 27, 2024
AU$15.75AU$15.34-2.60%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neuren Pharmaceuticals Limited (AU:NEU) report earnings?
Neuren Pharmaceuticals Limited (AU:NEU) is schdueled to report earning on Aug 25, 2026, TBA (Confirmed).
    What is Neuren Pharmaceuticals Limited (AU:NEU) earnings time?
    Neuren Pharmaceuticals Limited (AU:NEU) earnings time is at Aug 25, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Neuren Pharmaceuticals Limited stock?
          The P/E ratio of Neuren Pharmaceuticals Limited is N/A.
            What is AU:NEU EPS forecast?
            AU:NEU EPS forecast for the fiscal quarter 2026 (Q2) is 0.04.